Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.30310/fullpdf
Reference28 articles.
1. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis;Saag;Arthritis Rheum,2008
2. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis;Askling;Curr Opin Rheumatol,2008
3. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials;Bongartz;JAMA,2006
4. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists;Askling;Ann Rheum Dis,2007
5. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials;Bongartz;Ann Rheum Dis,2009
Cited by 126 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A state-of-the-art systematic review of cancer in hidradenitis suppurativa;Annals of Medicine;2024-07-24
2. Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry;Rheumatology and Therapy;2024-07-17
3. Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study;Journal of Cancer Research and Clinical Oncology;2023-09-27
4. Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms;Cells;2023-09-01
5. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3